Similar articles

• The tamoxifen-responsive estrogen receptor alpha mutant D351Y shows reduced tamoxifen-dependent interaction with corepressor complexes.

  Yamamoto Y, Wada O, Suzawa M, Yogiashi Y, Yano T, Kato S, Yanagisawa J. Yamamoto Y, et al. J Biol Chem. 2001 Nov 16;276(46):42684-91. doi: 10.1074/jbc.M107844200. Epub 2001 Sep 11. J Biol Chem. 2001. Retraction in: J Biol Chem. 2013 Oct 18;288(42):30506. doi: 10.1074/jbc.A113.107844. PMID: 11553641 Retracted.
• An antiestrogen-responsive estrogen receptor-alpha mutant (D351Y) shows weak AF-2 activity in the presence of tamoxifen.

  Webb P, Nguyen P, Valentine C, Weatherman RV, Scanlan TS, Kushner PJ. Webb P, et al. J Biol Chem. 2000 Dec 1;275(48):37552-8. doi: 10.1074/jbc.M007435200. J Biol Chem. 2000. PMID: 10986290
• Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen.

  Bentrem D, Dardes R, Liu H, MacGregor-Schafer J, Zapf J, Jordan V. Bentrem D, et al. Endocrinology. 2001 Feb;142(2):838-46. doi: 10.1210/endo.142.2.7932. Endocrinology. 2001. PMID: 11159857
• Role of estrogen receptor alpha transcriptional coregulators in tamoxifen resistance in breast cancer.

  Girault I, Bièche I, Lidereau R. Girault I, et al. Maturitas. 2006 Jul 20;54(4):342-51. doi: 10.1016/j.maturitas.2006.06.003. Epub 2006 Jul 5. Maturitas. 2006. PMID: 16822624 Review.
• Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.

  Michaud LB, Buzdar AU. Michaud LB, et al. Drugs Aging. 2000 Apr;16(4):261-71. doi: 10.2165/00002512-200016040-00002. Drugs Aging. 2000. PMID: 10874521 Review.